mifamurtide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
peptides and glycopeptides	2960	90825-43-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: MTP-PE mifamurtide hydrate muramyl tripeptide phosphatidyl ethanolamine mepact mifamurtide sodium mifamurtide junovan L-MTP-PE	Mifamurtide (muramyl tripeptide phosphatidyl ethanolamine, MTP-PE) is a fully synthetic derivative of muramyl dipeptide (MDP), the smallest naturally-occurring immune stimulatory component of cell walls from Mycobacterium sp. It has similar immunostimulatory effects as natural MDP with the additional advantage of a longer half-life in plasma. Mifamurtide liposomal formulation is specifically designed for in vivo targeting to macrophages by intravenous infusion. MTP-PE is a specific ligand of NOD2, a receptor found primarily on monocytes, dendritic cells and macrophages. MTP-PE is a potent activator of monocytes and macrophages. Activation of human macrophages by mifamurtide is associated with production of cytokines, including tumour necrosis factor (TNF-alfa), interleukin-1 (IL-1beta), IL-6, IL-8, and IL-12 and adhesion molecules, including lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1). In vitro-treated human monocytes killed allogeneic and autologous tumour cells (including melanoma, ovarian, colon, and renal carcinoma), but had no toxicity towards normal cells. Molecular weight: 1237.52 Formula: C59H109N6O19P CLOGP: 10.59 LIPINSKI: 4 HAC: 25 HDO: 10 TPSA: 376.10 ALOGS: -6 ROTB: 54

Molecule

Description

Molfile Inchi Smiles

Synonyms:

MTP-PE
mifamurtide hydrate
muramyl tripeptide phosphatidyl ethanolamine
mepact
mifamurtide sodium
mifamurtide
junovan
L-MTP-PE

Mifamurtide (muramyl tripeptide phosphatidyl ethanolamine, MTP-PE) is a fully synthetic derivative of muramyl dipeptide (MDP), the smallest naturally-occurring immune stimulatory component of cell walls from Mycobacterium sp. It has similar immunostimulatory effects as natural MDP with the additional advantage of a longer half-life in plasma. Mifamurtide liposomal formulation is specifically designed for in vivo targeting to macrophages by intravenous infusion. MTP-PE is a specific ligand of NOD2, a receptor found primarily on monocytes, dendritic cells and macrophages. MTP-PE is a potent activator of monocytes and macrophages. Activation of human macrophages by mifamurtide is associated with production of cytokines, including tumour necrosis factor (TNF-alfa), interleukin-1 (IL-1beta), IL-6, IL-8, and IL-12 and adhesion molecules, including lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1). In vitro-treated human monocytes killed allogeneic and autologous tumour cells (including melanoma, ovarian, colon, and renal carcinoma), but had no toxicity towards normal cells.

Molecular weight: 1237.52
Formula: C59H109N6O19P
CLOGP: 10.59
LIPINSKI: 4
HAC: 25
HDO: 10
TPSA: 376.10
ALOGS: -6
ROTB: 54

Drug dosage:

Dose	Unit	Route
0.70	mg	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	5.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	48.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.05 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 6, 2009	EMA	Takeda France SAS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug clearance decreased	60.60	59.87	10	201	3317	79740860

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L03AX15	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Other immunostimulants
MeSH PA	D000276	Adjuvants, Immunologic
MeSH PA	D007155	Immunologic Factors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteosarcoma of bone	indication	307576001	DOID:3376

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.61	acidic
pKa2	11.44	acidic
pKa3	12.45	acidic
pKa4	12.94	acidic
pKa5	13.24	acidic
pKa6	13.32	acidic
pKa7	13.64	acidic
pKa8	13.96	acidic
pKa9	13.98	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Nucleotide-binding oligomerization domain-containing protein 2	Cytosolic other	Q9HC29	NOD2_HUMAN	ACTIVATOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D06619	KEGG_DRUG
C0129341	UMLSCUI
CHEBI:135906	CHEBI
CHEMBL2111100	ChEMBL_ID
CHEMBL2107354	ChEMBL_ID
DB13615	DRUGBANK_ID
C037144	MESH_SUPPLEMENTAL_RECORD_UI
8274	IUPHAR_LIGAND_ID
1LM890Q4FY	UNII
013385	NDDF
710284002	SNOMEDCT_US
838853-48-8	SECONDARY_CAS_RN
11672602	PUBCHEM_CID

Pharmaceutical products:

None